Droplet microfluidics has revolutionized single-cell analysis, crucial for genomics, drug discovery, and diagnostics, by partitioning samples into nanoliter droplets for detailed cellular analysis. Yet, its broader adoption is hindered by the complex, costly methods required for analyzing droplets' optical properties.
This limitation underscores the urgent need for simpler, cost-effective optical sensing technologies to unlock the full potential of droplet microfluidics in various applications.
A study published on March 12, 2024, in the journal Microsystems & Nanoengineering, unveils an innovative technology that enables multiplexed fluorescence and scatter detection with unprecedented single-cell resolution, using on-chip fiber optics within droplet microfluidic applications.
The innovative technology behind the OptiDrop platform marks a significant departure from traditional single-cell analysis methods. By incorporating advanced optical fiber technology directly into microfluidic chips, OptiDrop enables on-chip detection of light scatter and fluorescence from droplets.
Mayo Clinic scientists have developed an immunotherapy strategy that potentially lays the groundwork for treating a spectrum of autoimmune diseases.
The new technique, detailed in a preclinical study published in Nature Biomedical Engineering, involves combining chimeric antigen receptors (CAR) with mesenchymal stromal cells (MSC), resulting in engineered stem cells known as CAR-MSCs.
"The pioneering approach shows potential in targeting inflammatory disease sites more precisely and improving immunosuppression and healing outcomes," says Saad Kenderian, M.B., Ch.B., a principal investigator and hematologist at Mayo Clinic. "We're planning to study interventions that minimize the need for long-term medications for autoimmune diseases."
The combination approach centers on mesenchymal stromal cells, which are found in various tissues in the body, including bone marrow, fat tissue and umbilical cord blood. These cells have the unique ability to transform into several specific types of cells such as bone cells, cartilage cells and fat cells.
World's most powerful MRI machine captures first stunning brain scans
By Michael Irving
April 02, 2024
The world’s most powerful MRI machine has started proving its worth, by scanning living human brains. The resulting images give an ultra high resolution glimpse into the brain, which will help us better understand the nature of consciousness and treat neurodegenerative diseases.
Developed by the French Alternative Energies and Atomic Energy Commission (CEA), the Iseult MRI machine packs a magnetic field strength of 11.7 Teslas (T). By comparison, conventional MRI machines in wide use in hospitals today are usually 1.5 or at most 3 T.
The main benefit of that extra power is that much higher resolution images of the brain can be taken, much quicker. In just four minutes, Iseult can capture images down to 0.2 mm (0.008 in) of brain tissue horizontally, in 'slices' just 1-mm (0.04-in) thick. That volume is the equivalent of a few thousand neurons at a time.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a burgeoning global health concern, posing a significant threat to public health and escalating the burden on health care resources. Characterized by the accumulation of fat in the liver, MASLD increases the risk of progressing to more severe conditions such as metabolic dysfunction-associated steatohepatitis (MASH), which is marked by inflammation, ballooning, and potential fibrosis.
In response to the pressing need for effective treatments for these metabolic disorders, researchers led by Prof. Jin Hee Ahn from Gwangju Institute of Science and Technology (GIST) developed compound 11c, a novel peripheral 5HT2A antagonist.
This research was made available online on January 20, 2024, and was published in Nature Communications, highlighting a significant therapeutic breakthrough. The compound showcased a promising profile and demonstrated efficacy in preclinical models, positioning it at the forefront of groundbreaking advancements in the field.
Scientists at King's College London have discovered a new cause for asthma that sparks hope for treatment that could prevent the life-threatening disease.
Most current asthma treatments stem from the idea that it is an inflammatory disease. Yet, the life-threatening feature of asthma is the attack or the constriction of airways, making breathing difficult. The new study, published in Science, shows for the first time that many features of an asthma attack—inflammation, mucus secretion, and damage to the airway barrier that prevents infections—result from this mechanical constriction in a mouse model.
The findings suggest that blocking a process that normally causes epithelial cell death could prevent the damage, inflammation, and mucus that result from an asthma attack.
In a transformative study published in the journal Science Translational Medicine, an international team of researchers has made a significant breakthrough in the understanding and potential treatment of multiple sclerosis (MS).
Their findings reveal the identification of three distinct immunological endophenotypes of MS, defined by specific blood immune signatures associated with different disease trajectories. This discovery opens new avenues for personalized treatment strategies, addressing the long-standing challenge of individualized treatment selection in MS therapy.
Recurrent UTIs banished for up to nine years by simple oral spray
By Paul McClure
April 07, 2024
An oral spray vaccine against recurrent urinary tract infections (UTIs) prevented the condition from returning for up to nine years in more than half of study participants, new research has shown. It offers a safe, effective method of UTI prevention and an alternative to antibiotic treatment.
UTIs are a pain – literally, a burning pain. Other symptoms, such as a strong urge to urinate that doesn’t go away, frequent urination, and a feeling of fullness even after urinating, are bad enough but made worse when the infection returns months later … and keeps returning.
Recurrent UTIs – defined as three or more UTIs in 12 months – occur in 20% to 30% of cases. Women are affected more than men simply because of their anatomy, with 80-85% of infections caused by the bacteria Escherichia coli. Klebsiella pneumoniae, Proteus vulgaris, and Enterococcus faecalis are other culprits. For this reason, antibiotics are often the first-line treatment. However, with the rise in antibiotic resistance, there’s a pressing need to find an effective alternative.
Over the past four years, many of us have become accustomed to a swab up the nose to test for COVID-19, using at-home rapid antigen tests or the more accurate clinic-provided PCR tests with a longer processing time. Now a new diagnostic tool developed by UC Santa Cruz Distinguished Professor of Electrical and Computer Engineering Holger Schmidt and his collaborators can test for SARS-CoV-2 and Zika virus with the same or better accuracy as high-precision PCR tests in a matter of hours.
In a paper in the journal Proceedings of the National Academy of Sciences, Schmidt and the project team describe their system, which combines optofluidics and nanopore technology to create a lab-on-a-chip diagnostic system. The team's success with animal models makes them hopeful that this technology could be a major innovation for the future of rapid diagnostics.
